News

An investigational treatment for Alzheimer’s disease (AD) could be on the horizon, according to a study from researchers at Biogen and the University of Zurich. Aducanumab, a human monoclonal antibody, shows evidence of reducing Alzheimer’s amyloid plaques — the culprit behind AD-induced brain cell death. The treatment candidate is potentially…

Researchers announced the start of what is being called the largest and most thorough study yet undertaken to identify biomarkers of Alzheimer’s disease before symptoms occur. Such findings could help determine the success of Alzheimer clinical trials and lead to earlier diagnoses. The British effort involves the translational research firm Imanova,…

At the recent Alzheimer’s Association International Conference (AAIC) 2016, held in Toronto, Canada, Muses Labs presented data from a pilot study of its MEND Protocol for treatment of early Alzheimer’s disease. The few drugs available today to slow the progression of Alzheimer’s disease target individual brain factors. Plenty of research,…

A variety of shark species from the Atlantic and Pacific Oceans have high concentrations of two toxins linked to neurodegenerative diseases like Alzheimer’s in their fins and muscles, according to researchers at the University of Miami. Their study, “Cyanobacterial Neurotoxin BMAA and Mercury in Sharks,”…

The rate of Alzheimer’s disease (AD) is increasing worldwide with the most significant risk factors appearing to be associated with diet, particularly the consumption of sweets, meat, and high-fat dairy products common in the Western diet, according to a new study report. For example, during Japan’s transition from the Japanese diet to the…

Regular physical activity, normal body mass index (BMI), and a healthy diet may prevent the onset of Alzheimer’s disease by reducing the incidence of protein aggregates in the brain, according to a study that will appear in the September issue of the American Journal of Geriatric Psychiatry.

New York City’s Alzheimer’s and dementia expert organization, CaringKind, announced the recent appointment of Niurqui “Nikki” Mariano as its new manager of healthcare outreach. CaringKind, previously known as the New York City chapter of the Alzheimer’s Association, has over three decades of experience in working with dementia and Alzheimer’s…

Recent research has shed new light on genetic mechanisms involved in the process of neurodegenerative disease development. Neurodegenerative disorders including Alzheimer’s, Huntington’s and Parkinson’s are conditions characterized by the progressive loss of structure and function of neurons that eventually lead to the neuron’s death. These conditions involve complex processes and mechanisms that render the…

Neurotrope BioScience has submitted an amended protocol to the U.S. Food and Drug Administration (FDA) for a Phase 2b clinical trial of its lead product candidate bryostatin-1 for treating advanced Alzheimer’s disease. The company said in a press release that in the original trial protocol, the primary efficacy outcome is…

ProMIS Neurosciences reported progress of drug discovery technologies at the recent Alzheimer’s Association International Conference (AAIC) meeting, held in Toronto, Canada, showing that the technologies specifically target certain forms of amyloid-beta and tau in Alzheimer’s disease. The company works to identify structures on the surface of the toxic variants of…